TP53 and neoplasm: A recent genetic and transcriptomic study on 148 osteosarcoma patients published by Saba, Difilippo et al. [7] provides a novel paradigm in which TP53 rearrangements can simultaneously result in inactivation of p53 tumour suppressor functions and activation of oncogenic pathways by fusing the TP53 promoter region to new target genes (promoter swapping).